Literature DB >> 30670595

Overexpression of the C-domain of angiotensin-converting enzyme reduces melanoma growth by stimulating M1 macrophage polarization.

Zakir Khan1,2, Duo-Yao Cao1, Jorge F Giani1, Ellen A Bernstein1, Luciana C Veiras1, Sebastien Fuchs3, Yizhou Wang1,4, Zhenzi Peng1, Markus Kalkum5, George Y Liu1,6, Kenneth E Bernstein7,2.   

Abstract

Angiotensin-converting enzyme (ACE) can hydrolyze many peptides and plays a central role in controlling blood pressure. Moreover, ACE overexpression in monocytes and macrophages increases resistance of mice to tumor growth. ACE is composed of two independent catalytic domains. Here, to investigate the specific role of each domain in tumor resistance, we overexpressed either WT ACE (Tg-ACE mice) or ACE lacking N- or C-domain catalytic activity (Tg-NKO and Tg-CKO mice) in the myeloid cells of mice. Tg-ACE and Tg-NKO mice exhibited strongly suppressed growth of B16-F10 melanoma because of increased ACE expression in macrophages, whereas Tg-CKO mice resisted melanoma no better than WT animals. The effect of ACE overexpression reverted to that of the WT enzyme with an ACE inhibitor but not with an angiotensin II type 1 (AT1) receptor antagonist. ACE C-domain overexpression in macrophages drove them toward a pronounced M1 phenotype upon tumor stimulation, with increased activation of NF-κB and signal transducer and activator of transcription 1 (STAT1) and decreased STAT3 and STAT6 activation. Tumor necrosis factor α (TNFα) is important for M1 activation, and TNFα blockade reverted Tg-NKO macrophages to a WT phenotype. Increased ACE C-domain expression increased the levels of reactive oxygen species (ROS) and of the transcription factor C/EBPβ in macrophages, important stimuli for TNFα expression, and decreased expression of several M2 markers, including interleukin-4Rα. Natural ACE C-domain-specific substrates are not well-described, and we propose that the peptide(s) responsible for the striking ACE-mediated enhancement of myeloid function are substrates/products of the ACE C-domain.
© 2019 Khan et al.

Entities:  

Keywords:  ACE; Macrophage polarization; NF-kappa B (NF-KB); STAT; cellular immune response; macrophage; melanoma; tumor necrosis factor (TNF)

Mesh:

Substances:

Year:  2019        PMID: 30670595      PMCID: PMC6433053          DOI: 10.1074/jbc.RA118.006275

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

Review 1.  Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme.

Authors:  Sebastien Fuchs; Kristen Frenzel; Hong D Xiao; Jonathan W Adams; Hui Zhao; George Keshelava; Lu Teng; Kenneth E Bernstein
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

Review 2.  Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease.

Authors:  Steven J Van Dyken; Richard M Locksley
Journal:  Annu Rev Immunol       Date:  2013-01-03       Impact factor: 28.527

3.  A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model.

Authors:  Li Ma; Haiyan Gong; Haiyan Zhu; Qing Ji; Pei Su; Peng Liu; Shannan Cao; Jianfeng Yao; Linlin Jiang; Mingzhe Han; Xiaotong Ma; Dongsheng Xiong; Hongbo R Luo; Fei Wang; Jiaxi Zhou; Yuanfu Xu
Journal:  J Biol Chem       Date:  2014-03-14       Impact factor: 5.157

Review 4.  Angiotensin-converting enzyme overexpression in myelocytes enhances the immune response.

Authors:  Kenneth E Bernstein; Romer A Gonzalez-Villalobos; Jorge F Giani; Kandarp Shah; Ellen Bernstein; Tea Janjulia; Yosef Koronyo; Peng D Shi; Maya Koronyo-Hamaoui; Sebastien Fuchs; Xiao Z Shen
Journal:  Biol Chem       Date:  2014-10       Impact factor: 3.915

5.  Enhanced expression of angiotensin-converting enzyme is associated with progression of coronary atherosclerosis in humans.

Authors:  M Ohishi; M Ueda; H Rakugi; T Naruko; A Kojima; A Okamura; J Higaki; T Ogihara
Journal:  J Hypertens       Date:  1997-11       Impact factor: 4.844

6.  Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines.

Authors:  I J Fidler; G L Nicolson
Journal:  J Natl Cancer Inst       Date:  1976-11       Impact factor: 13.506

7.  Clinical and biochemical aspects of sarcoidosis. With special reference to angiotensin-converting enzyme (ACE).

Authors:  F K Rømer
Journal:  Acta Med Scand Suppl       Date:  1984

8.  The carboxypeptidase ACE shapes the MHC class I peptide repertoire.

Authors:  Xiao Z Shen; Sandrine Billet; Chentao Lin; Derick Okwan-Duodu; Xu Chen; Aron E Lukacher; Kenneth E Bernstein
Journal:  Nat Immunol       Date:  2011-10-02       Impact factor: 25.606

Review 9.  Molecular mechanisms that influence the macrophage m1-m2 polarization balance.

Authors:  Nan Wang; Hongwei Liang; Ke Zen
Journal:  Front Immunol       Date:  2014-11-28       Impact factor: 7.561

10.  Myeloid expression of angiotensin-converting enzyme facilitates myeloid maturation and inhibits the development of myeloid-derived suppressor cells.

Authors:  Xiao Z Shen; Derick Okwan-Duodu; Wendell-Lamar Blackwell; Frank S Ong; Tea Janjulia; Ellen A Bernstein; Sebastien Fuchs; Serhan Alkan; Kenneth E Bernstein
Journal:  Lab Invest       Date:  2014-03-10       Impact factor: 5.662

View more
  10 in total

1.  ACE overexpression in myeloid cells increases oxidative metabolism and cellular ATP.

Authors:  Duo-Yao Cao; Weston R Spivia; Luciana C Veiras; Zakir Khan; Zhenzi Peng; Anthony E Jones; Ellen A Bernstein; Suguru Saito; Derick Okwan-Duodu; Sarah J Parker; Jorge F Giani; Ajit S Divakaruni; Jennifer E Van Eyk; Kenneth E Bernstein
Journal:  J Biol Chem       Date:  2019-12-23       Impact factor: 5.157

2.  Epigenetic control of the angiotensin-converting enzyme in endothelial cells during inflammation.

Authors:  Thomas Mudersbach; Daniel Siuda; Karin Kohlstedt; Ingrid Fleming
Journal:  PLoS One       Date:  2019-05-01       Impact factor: 3.240

3.  Margatoxin mitigates CCl4‑induced hepatic fibrosis in mice via macrophage polarization, cytokine secretion and STAT signaling.

Authors:  Bao-Ming Wu; Jun-Da Liu; Yuan-Hai Li; Jun Li
Journal:  Int J Mol Med       Date:  2019-11-04       Impact factor: 4.101

Review 4.  Role of angiotensin-converting enzyme in myeloid cell immune responses.

Authors:  Duo-Yao Cao; Suguru Saito; Luciana C Veiras; Derick Okwan-Duodu; Ellen A Bernstein; Jorge F Giani; Kenneth E Bernstein; Zakir Khan
Journal:  Cell Mol Biol Lett       Date:  2020-05-25       Impact factor: 5.787

5.  LncGBP9/miR-34a axis drives macrophages toward a phenotype conducive for spinal cord injury repair via STAT1/STAT6 and SOCS3.

Authors:  Jiahui Zhou; Zhiyue Li; Tianding Wu; Qun Zhao; Qiancheng Zhao; Yong Cao
Journal:  J Neuroinflammation       Date:  2020-04-28       Impact factor: 8.322

6.  A Nomogram Combining a Four-Gene Biomarker and Clinical Factors for Predicting Survival of Melanoma.

Authors:  Chuan Zhang; Dan Dang; Yuqian Wang; Xianling Cong
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

Review 7.  Exploring the Impact of ACE Inhibition in Immunity and Disease.

Authors:  Delia Oosthuizen; Edward D Sturrock
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2022-08-04       Impact factor: 4.109

8.  ACE-domain selectivity extends beyond direct interacting residues at the active site.

Authors:  Gyles E Cozier; Lizelle Lubbe; Edward D Sturrock; K Ravi Acharya
Journal:  Biochem J       Date:  2020-04-17       Impact factor: 3.857

9.  Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.

Authors:  Soleine Medjebar; Caroline Truntzer; Anaïs Perrichet; Emeric Limagne; Jean-David Fumet; Corentin Richard; Arielle Elkrief; Bertrand Routy; Cédric Rébé; François Ghiringhelli
Journal:  Oncoimmunology       Date:  2020-10-27       Impact factor: 8.110

10.  Astragaloside IV Alleviates the Experimental DSS-Induced Colitis by Remodeling Macrophage Polarization Through STAT Signaling.

Authors:  Lianlian Tian; Jun-Long Zhao; Jian-Qin Kang; Shi-Bo Guo; Nini Zhang; Lei Shang; Ya-Long Zhang; Jian Zhang; Xun Jiang; Yan Lin
Journal:  Front Immunol       Date:  2021-09-13       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.